big boost for biota, page-15

CPG

You are on the money.

DMA

If the Asian trials are successful and I am confident they will be, GSK management will still just be doing the minimum and going through the motions.

You would have thought with a disease as deadly as Avian Flu with no margin for error. No margin in the sense that there will be no time to switch treatments if the first one does not work. The first drug of choice should be based on viral resistance not ease of taking.

This is not like a bacterial infection which allows the Doctor to change drugs if the first one does not work.

MISO

????